Date de publication: 21 mars 2022
Promoteur – Intermédiaire Financier
UCB SALieu
Description
The project concerns investments in research and development (R&D) activities and in the construction of an advanced manufacturing plant that will be located in existing promoter facilities in Belgium.
Objectifs
The project aims at improving the health of European citizens, increasing the competitiveness and boosting the innovative capacity of European health-related industries and businesses. The project focuses on neuroscience and immunology in particular neuro-degeneration, neuro-inflammation and rare diseases as well as autoimmune diseases, which are mostly still underserved and leave a high clinical unmet need.
Secteur(s)
- Industrie - Industrie manufacturière
Montant BEI envisagé (montant approximatif)
EUR 350 million
Coût total (montant approximatif)
EUR 975 million
Aspects environnementaux
The project includes the construction of a new plant to manufacture pharmaceutical products. This activity is listed in the Annex II of the Environmental Impact Assessment (EIA) Directive. Whether a EIA under the directive 2014/52/EU is required and other environmental details will be verified during the project appraisal.
Passation des marchés
The Promoter is a private company not operating in the Utilities sector and not having a status of a contracting entity. Thus it is not covered by EU Directives on procurement.
Statut
Signé - 18/11/2021
Clause de non-responsabilité
Avant d’être approuvés par le Conseil d’administration et avant la signature des prêts correspondants, les projets font l’objet d’une instruction et de négociations. Par conséquent, les informations et données fournies sur cette page sont indicatives.
Elles sont fournies à des fins de transparence uniquement et ne peuvent être considérées comme représentant la politique officielle de la BEI (voir également les notes explicatives).